Clinical Trials Logo

Neoplasms, Rectal clinical trials

View clinical trials related to Neoplasms, Rectal.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05723562 Recruiting - Neoplasms, Rectal Clinical Trials

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

AZUR-1
Start date: April 3, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment. Participants who achieve complete clinical response (cCR) following dostarlimab treatment will undergo non-operative management (NOM), including close surveillance for recurrent disease. The goal of the study is to determine if Dostarlimab therapy alone is an effective treatment that can allow participants to avoid chemotherapy, radiation, and surgery.

NCT ID: NCT03573791 Recruiting - Rectal Cancer Clinical Trials

Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer

Start date: May 21, 2018
Phase:
Study type: Observational

Neoadjuvant therapy has been widely applied to locally advanced rectal cancer. However, about 50% of patients receiving this therapy do not respond well as evidenced by the fact that their T or N stages are not effectively decreased judged by postoperative pathological examination. The purpose of this trail is to identify the biomarkers (from within patients' tumor mass before neoadjuvant therapy) to predict resistance to neoadjuvant therapy. These biomarkers can help stratify neoadjuvant-resistant patients towards surgery while avoiding unnecessary chemoradio-based neoadjuvant therapy.